Safety and Immunogenicity of ChulaCov19 BNA159 mRNA Vaccine

NCT05231369 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Safety of 25 ug of ChulaCov19-BNA159 mRNA Vaccine
Tolerability of 25 ug of ChulaCov19-BNA159 mRNA Vaccine
Immune Response of 25 ug of ChulaCov19-BNA159 mRNA Vaccine
Safety of 50 ug of ChulaCov19-BNA159 mRNA Vaccine
Tolerability of 50 ug of ChulaCov19-BNA159 mRNA Vaccine
Immune Response of 50 ug of ChulaCov19-BNA159 mRNA Vaccine
Assess Which Dose is Appropriate to Use

Interventions

BIOLOGICAL: ChulaCov19 BNA159 mRNA vaccine

Sponsor

Chulalongkorn University

Collaborators

[object Object]
[object Object]